 |
Publications
The following is a list of common topics that I have presented to Physician groups at various hospital grand rounds, staff meetings, and society meetings. I try to update this list on an annual basis and am always able to arrange lectures on specific topics that concern the medical staff, even if not listed.
NOTE: I would also be willing the speak on any other topic in the field of Allergy & Clinical Immunology. PHYSICIAN'S LECTURES ON ABOVE TOPICS:
NOTE: 2005 Lecture Schedule presently being arranged. The simplest way for arranging a presentation for Medical staff is to contact me directly at our main office at (858) 271-1151. I have also prepared and given numerous lectures & seminars to non-medical personnel including senior citizen groups, church and temple organizations, parent-teacher organizations, etc. I have also given lectures to other medical personnel including hospital nursing staffs as well as the S.D. Unified School Nurses. TITLE: PHASE III STUDY OF THE EFFECTS OF ZILEUTON, 400 MG QID AND 600 MG QID, AND PLACEBO IN MODERATE ASTHMA PROTOCOL M92-720 SPONSOR: ABBOTT LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: PHASE III STUDY OF THE EFFECTS OF ZILEUTON 600 MG QID IN PATIENTS WITH MODERATE ASTHMA COMPLETING PROTOCOL M-92-720 PROTOCOL M92-801 SPONSOR: ABBOTT LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: LONG TERM SURVEILLANCE STUDY OF ZILEUTON PLUS USUAL CARE VERSUS USUAL CARE IN PATIENTS WITH ASTHMA PROTOCOL M94-199 SPONSOR: ABBOTT LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP COMPARISON OF FLUTICASONE PROPIONATE QUUEOUS NASAL SPRAY VERSUS ENCAPSULATED LORATADINE TABLETS VERSUS A COMBINATION OF FLUTICASONE AND LORATADINE VERSUS PLACEBO FOR TWO WEEKS IN SUBJECTS WITH SEASONAL ALLERGIC RHINITIS PROTOCOL FLTA 4024 SPONSOR: GLAXO WELLCOME SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF LUTICASONE PROPIONATE AQUEOUS NASAL SPRAY VERSUS PLACEBO FOLLOWED BY A SIX MONTH OPEN LABEL SAFETY EXTENSION I N SUBJECTS WITH PERENNIAL NON-ALLERGIC RHINITIS PORTOCOL FLTA 3010 SPONSOR: GLAXO WELLCOME SUB-INVESTIGATOR: GARY A. COHEN,MD TITLE: FORMOTEROL DRY POWDER (CGP-25827A) A TWELVE WEEK DOUBLE BLIND, PARALLEL GROUP TRIAL COMPARING THE SAFETY, TOLERABILITY AND EFFICACY OF FORMOTEROL DRY POWDER CAPSULES FOR INHALATION DELIVERED BY A SINGLE DOSE INHALER VERSUS ALBUTEROL METERED DOSE INHALER (MDI) VERSUS PLACEBO IN PATIENTS WITH MILD TO MODERATE ASTHMA PROTOCOL 40 SPONSOR: CIBA-GEIGY CORPORATION SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, GROUP COMPARATIVE STUDY OF THE EFFICACY OF NEDOCROMIL SODIUM 0.5% NEBULIZER SOLUTION (TID) IN THE TREATMENT OF CHILDREN 5-11 YEARS OF AGE WITH BRONCHIAL ASTHMA PROTOCOL 1241-3003 SPONSOR: FISONS CORPORATION SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, GROUP COMPARATIVE STUDY OF THE SAFETY AND EFFECTIVENESS OF NEDOCROMIL SODIUM (TILADE®) 4 MG QID VS PLACEBO ADMINISTERED VIA METERED DOSE INHALER (MDI) PROTOCOL 1241-2338 SPONSOR: FISONS CORPORATION SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: OPEN LABEL MULTICENTER STUDY FO THE SAFETY OF NEDOCROMIL SOIDUM (TILADE®) 4 MG QID ADMINISTERED VIA METERED DOSE INHALER (MDI) IN THE MANAGEMENT OF BROHCHIAL ASTHMA IN CHILDREN PROTOCOL 1231-2339 SPONSOR: FISONS CORPORATION SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: PILOT STUDY TO EVALUATE THE EFFICACY, TOLERABILITY AND SAFETY OF TWO DOSES OF HOE 1401 (ICATIBANT) IN COMPARISON TO PLACEBO IN THE TREATMENT OF BRONCHIAL ASTHMA PROTOCOL LEV-USA-1 SPONSOR: HOESCHST-ROUSSEL PHARMACEUTICAL SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: PROTOCOL TO DETERMINE THE SAFETY AND EFFICACY OF LEVOCABASTINE NASAL SPRAY IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS, DOUBLE BLIND EVALUATION OF LEVOCABASTINE GIVEN FOUR TIMES A DAY, OR TWICE A DAY VS PLACEBO PROTOCOL LEV-USA-1 SPONSOR: JANSSEN RESEARCH FOUNDATION SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING THE CLINICAL EFFECT OF FIVE ORAL DOSES OF MK-0476 AND PLACEBO IN PATIENTS WITH STABLE, MODERATE ASTHMA PROTOCOL 009-01 SPONSOR: MERCK RESEARCH LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: AN OPNE EXTENSION TO THE MK-0476 DOSE RANGING STUDY TO INVESTIGATE SAFETY AND TOLERABILITY OF MK-0476 IN PATIENTS WITH CHRONIC ASTHMA PROTOCOL 009-11 SPONSOR: MERCK RESEARCH LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: AN OPEN EXTENSION TO THE MK-0476 DOSE RANGING STUDY TO INVESTIGATE SAFETY AND TOLERABILITY OF MK-0476 IN PATIENTS WITH CHRONIC ASTHMA PROTOCOL 009-12 SPONSOR: MERCK RESEARCH LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING THE CLINICAL EFFECT OF THREE ORAL DOSES OF MK-0476 AND PLACEBO IN ADULT PATIENTS WITH STABLE, MODERATE ASHTMA PROTOCOL 025-01 SPONSOR: MERCK RESEARCH LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING THE CLINICAL EFFECT OF MK-0476 AND PLACEBO IN PATIENTS WITH CHRONIC ASTHMA PROTOCOL 031-01 SPONSOR: MERCK RESEARCH LABORATORIES SUB-INVESTOGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING THE CLINICAL EFFECT OF MK-0476 TO PLACEBO IN PATIENTS WITH CHRONIC ASTHMA PROTOCOL 031-02 OPEN LABEL EXTENSION SPONOSR: MERCK RESEARCH LABORATORIES SUB-INVESTOGATOR: GARY A. COHEN, MD TITLE: A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, TRIAL OF THE SAFETY AND EFFICACY OF ORAL BAYX1005 (100 MG BID VS 250 MG BID VS 500 MG BID VS PLACEBO FOR 6 WEEKS) IN PATIENTS WITH ASTHMA PROTOCOL D93-024 SPONSOR: MILES, INC. SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARRALLEL GROUP FACTORIAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF VARIOUS DOSES OF ENALAPRIL ADMINISTERED CONCOMITANTLY WITH VARIOUS DOES OF LOSARTAN IN PATIENTS WITH MILD TO MODERATE HYPERTENSION PROTOCOL 157-00 SPONSOR: MERCK RESEARCH LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A PLACEBO CONTROLLED DOUBLE BLIND, RANDOMIZED, PARALLEL STUDY COMPARING DURATION OF ACTION AND SAFETY AND EFFECTIVENESS OF FOUR DOSAGE STRENGTHS OF MDL 16,4551 IN THE TREATMENT OF SPRING ALLERGIES 1 & II PJPROO9 (I) & PFPROO10 (II) PROTOCOL PJPROOO9 SPONSOR: MARION MERRELL DOW, INC. SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A TWELVE MONTH SAFETY TOLERANCE STUDY OF 240 MG MDL 16,455A QD AND PLACEBO QD IN NORMAL HEALTHY SUBJECTS PROTOCOL 016455PR0027 SPONSOR: MARION MERRELL DOW, INC SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED SUDY OF THE EFFICACY AND SAFETY OF FOUR WEEKS TREATMENT WITH ORAL CP-80,633 IN ADULT PATIENTS WITH CHRONIC, MILD TO MODERATE ASTHMA PROTOCOL 016455PR0027 SPONSOR: MARION MERRELL DOW, INC. SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PALCEBO CONTROLLED STUDY OF THE EFFICACY AND SAFAETY OF FOUR WEEKS TREATMENT WITH ORAL CP-80,633 IN ADULT PATIENTS WITH CHRINIC, MILT TO MODERATE ASTHMA PROTOCOL 149-103-525 SPONSOR: PFIZER INC. SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A LONG TERM SAFETY STUDY OF SCH 32088 VS NASACORT® IN PERENNIAL RHINITIS PROTOCOL C94-052-16 SPONSOR: SCHERING-PLOUGH RESEARCH INSTITUTE SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A STUDY FO THE EFFECTS OF INTRANASAL STEROIDS (BECLOMETHASONE DEIPROIONATE) ON THE GROWTH AND HPA AXIS FUNCTION OF CHILDREN PROTOCOL C93-048-04 SPONSOR: SCHERING-PLOUGH RESEARCH INSTITUTE SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLEED TRIAL OF ZAFIRLUKAST (ACCOLATE) IN SUBJECTS WITH MILD TO MODERATE ASTHMA 3 WEEKS EFFICACY AND UP TO 52 WEEKS OPEN LABEL SAFETY EXTENSION PROTOCOL 3788IL/0095 SPONSOR: ZENECA PHARMACEUTICALS SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, 13 WEEK TRIAL COMPARING TWO DOES OF ZAFIRLUKAST (ACCOLATE) IN COMBINATION WITH LOW-DOSE INHALED CORTICOSTEROIDS VS HIGH-DOSE CORTICOSTEROIDS ALONE IN SUBJECTS WITH MILD TO MODERATE ASTHMA PROTOCOL 9188IL/0094 SPONSOR: ZENECA PHARMACEUTICALS SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP COMPARISON OF THE SAFETY AND EFFICACY OF TWO DOSES OF BAY X7195 AEROSOL WITH PALCEBO IN PATIENTS WITH ASTHMA PROTOCOL D95-016 SPONSOR: BAYER CORPORATION SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: SAFETY AND EFFICACY OF ABT761 150 MG, 300 MG QD VS PLACBO IN PATIENTS WITH MODERATE ASTHMA, PIVOTAL NO.2 PROTOCOL M96-441 SPONSOR: ABBOTT LABORATORIES SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A LONG TERM OPEN LABEL, MULTICENTER STUDY OF ONCE DAILY ORAL SK & F 108566 IN PATIENTS WITH ESSENTIAL HYPERTENSION PROTOCOL 050 SPONSOR: SMITHKLINE BEECHAM PAHRMACEUTICALS SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER TRIAL OF THE ANTIHYPERTENSIVE ACTIVITY AND SAFETY OF IRBESARTAN IN PATIENTS WITH MILD TO MODERATE HYPERTENSION PROTOCOL CV131-050 SPONSOR: BRISSTOL-MYERS SQUIBB SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: AN OPNE LABEL LONG-TERM TRAIL EVALUATING THE SAFETY OF BMS-180048 75 MG IN THE TREATMENTOF PATIENTS WITH MIGRAINE HEADACHE WITH OR WITHOUT AURA PROTOCOL CN115-038 SPONSOR: BRISTOL-MYERS SQUIBB SUB-INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLINE, PARRELLE GROUP, COMPARATIVE TRIAL EVALUATING FLUTICASONE PROPIONATE (220 MCG BID), TRIAMCINOLONE ACETONIDE (600 MCG BID), AND FLUTICASONE PROPIONATE (88MCG BID) IN COMBINATION WITH SALMETEROL XINAFOATE 42 MCG BID) EACH DELIVERED VIA A METERED DOSE INHALER, IN SUBJECTS WITH ASTHMA WHO REMAIN SYMPTOMATIC DESPITE RECEIVING INHALED CORTICOSTEROIDS PROTOCOL FLTA 4022 SPONSOR: GLAXO WELLCOME PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A DOSE RANGING, SAFETY AND EFFICACY TRIAL WITH ZAFIRLUKAST (ACCOLATE®) IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH MILD TO MODERATE ASTHMA PROTOCOL 9188IL/0139 SPONSOR: ZENECA PHARMACEUTICALS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED, PARELLE GROUP COMPARATIVE STUDY OF INHALED FLUTICASONE PROPIONATE (88MCG) VS ZFIRLUKAST (20 MG BID) IN SUBJECTS WHO ARE CURRENTLY RECEIVING BET AGONISTS ALONE PROTOCOL FLTA 4030 SPONSOR: GLAXO WELLCOME PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: AN OPEN LABEL, MULTICENTER STUDY OF EFFICACY, SAFETY, AND EFFECT OF QOL OF ZYRTEC (CETIRIZINE HCI) SYRUP IN THE TREATMENTOF SEASONAL ALLERGIC RHINITIS IN CHILDREN PROTOCOL L-0350 SPONSOR: PFIZER PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A PLACEBO CONTROLLED DOSE RANGING STUDY OF MOMETASONE FUROATE HFA-227 METERED DOSE INHALER COMPARED TO BECLOMETHASONE DIPROPIONATE ( VANCERIL 84 MCG DOUBLE STRENGTH) IN THE TREATMENT OF ASTHMA IN SUBJECTS PREVIOUSLY MAINTAINED ON INHALED CORTICOSTEROIDS PROTOCOL C97-222-08 SPONSOR: SCHERING-PLOUGH PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A DOUBLE BLIND, PLACEBO CONTROLLED EXPLORATORY SAFETY AND EFFICACY EVALUATION OF VP-63843 (PLECONARIL) IN THE TREATMENT OF EVTEROVIRAL UPPER RESPIRATORY TRACT DISEASE PROTOCOL 843-010 SPONSOR: VIROPHARMA PAHRMACEUTICALS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A DOSE RANGING, SAFETY AND EFFICACY TRIAL OF ZAFIRLUKAST (ACCOLATE) IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH MILD TO MODERATE ASTHMA FOR 52 WEEKS PROTOCOL 9188.0139 OPEN LABEL SPONSOR: ZENECA PHARMACEUTICALS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, COMPARISON OF INHALED SALMETEROL XINAFOATE (42 MCG BID) WITH ORAL ZIFIRLUKAST (20 MG BID) IN SUBJECTS WITH MILD TO MODERATE ASTHMA PROTOCOL SLGA5025 SPONSOR: SCHERING-PLOUGH PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A ONE YEAR OPEN LABEL SAFETY STUDY OF MOMETASONE FUROATE DRY POWDER INHALER MF DPI AND BECLOMETHASONE DIPROPIONATE (VANCERIL 84 MCG DOUBLE STRENGTH) IN CHILDREN WITH ASTHMA PREVIOUSLY MAINTAINED ON INHALED CORTICOSTEROIDS PROTOCOL C970385 SPONSOR: SCHERING-PLOUGH PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A PLACEBO CONTROLLED DOSE EFFICACY AND SAFETY STUDY OF MOMETASONE FUROATE DRY POWDER INHALER MF DPI IN THE TREATMENT OF ASTHMA IN CHILDREN PREVIOUSLY MAINTAINED ON BECLOMETHASONE DEPROPIONATE (VANCERIL 84 MCG DOUBLE STRENGTH) PROTOCOL C97-380 SPONSOR: SCHERING-PLOUGH PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: COMPARATIVE SAFETY AND EFFICACY OF CEFDITOREN PIVOXIL AND CEFUROXIME AXETIL IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS PROTOCOL CEF-97-003 SPONSOR: TAP HOLDINGS INC. PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL FOR SAFETY AND EFFICACY EVALUATION OF PLECONARIL IN THE TREATMENT OF VIRAL SYNDROME PROTOCOL 843-020 SPONSOR: VIROPHARMA INC. PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP COMPARATIVE STUDY OF INHALED FLUTICASONE PROPIONATE (88MCG BID) VS MONTELUKAST DODIUM (10 MG QD) IN SUBJECTS WHO ARE RECEIVING BETA AGAONISTS ALONE PROTOCOL FLTA4038 SPONSOR: GLAXO WELLCOME PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMEZED, DOUBLE BLIND, DOUBLE DUMMY, PARALLEL GROUP COMPARATIVE STUDY OF INHALED FLUTICASONE PROPIONATE (88MCG BID) VS ZAFIRLUKAST (20 MG BID) IN ASTHMATIC SUBJECTS WHO ARE CURRENTLY RECEIVING LOW DOSE INHALED CORITCOSTEROIDS PROTOCOL FLTA 4035 SPONSOR: GLAXO WELLCOME PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF TREATMENT OF SEASONAL ALLRGIC RHINITIS (sar) IN SUBJECTS WITH CO-MORBID ASTHMA AND A HISTORY OF SEASONAL EXACERBATIONS OF ASTHMA ON MEDICAL RESOURCES UTILIZATION FOR ASTHMA AND sar PROTOCOL P97-293 SPONSOR: INTEGRATED THERAPTEUTICS GROUP, DIVISION OF SCHERING PLOUGH PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIDN, DOUBLE DUMMY, PARALLEL GROUP COMPARISON OF SALMETEROL XINAFOATE INHALATION POWDER (50MCG BID) WITH ORAL MONTELUKAST (10 MG QD) IN SUBJECTS WITH PERSISTENT ASTHMA SYMPTOMATIC ON CONCIMITANT INHALED CORTICOSTEROID THERAPY PROTOCOL SMS40004 SPONSOR: GLAXO WELLCOME PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A COMPARATIVE SAFETY AND EFFICACY OF CEFDITOREN PIVOXIL AND CLARITHOMYCIN IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS PROTOCOL CEF-97-005 SPONSOR: TAP HOLDINGS INC. PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A COMPARATIVE SAFETY AND EFFICACY OF CEFDITOREN PIVOXIL AND AMOXILILLIN/CLAVULANATE (AUGMENTIN) IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA PROTOCOL CEF-97-006 SPONSOR: TAP HOLDINGS INC. PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, PARELLEL GROUP, OPEN LABEL, MULTICENTER CLINICAL STUDY COMPARING THE SAFETY, EFFICACY, QUALITY OF LIFE AND SOCIOECONIMIC VARIABLES OF TWICE DAILY FORMOTEROL POWDER (12 MG BID) TO TWICE DAILY SALMETEROL (50 MG BID) ADMINISTERED FOR SIX MONTHS TO ADULT SUBJECTS WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE (ROAD) PROTOCOL FORADIL 073 SPONSOR: NOVARTIS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, COMPARATIVE STUDY OF CEFPROZIL VS CLARITHOMCIN IN THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS PROTOCOL A1414.163 SPONSOR: BRISTOL-MYERS SQUIBB PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: EVALUATION OF THE SAFETY AND EFFICACY OF THREE ORAL DOSES OF ABT-773 IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS PROTOCOL M99-048 SPONSOR: ABBOTT LABORATORIES PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS PROTOCOL M00-216 SPONSOR: ABBOTT LABORATORIES PRIMARY INVESTIGATOR: GARY A.COHEN, MD TITLE: MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE SAFETY OF ZYRTEC SYRUP IN PEDIATRIC SUBJECTS 6 MOS. TO 11 MONTHS OF AGE PROTOCOL A1431010 SPONSOR: PFIZER PHARMACEUTICALS GROUP PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: COMPARATIVE STUDY OF SAFETY OF ABT-492 100 MG QD, 200 MG QD, 400 MG QD, AND LEVOFLOXACIN 500 MG QD FOR THE TREATMENT OF SUBJECTS WITH ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS PROTOCOL M01-298 SPONSOR: ABBOTT LABORATORIES PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A DOUBLE BLIND, PLACEBO CONTROLLED, LONG TERM GROWTH STUDY OF HFA FLUNISOLIDE IN CHILDREN WITH MILD ASTHMA PROTOCOL ANC-MD-07 SPONSOR: ABBOTT LABORATORIES PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A PHASE III DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER EFFICACY, SAFETY AND DOSE RESPONSIVE STUDY OF CICLESONIDE MDI 100 MCG/200 MCG/DAY AND 400 MCG/DAY ADMINISTERED DAILY FOR 12 WEEKS IN MODERATE PERSISTENT ASTHMA IN ADOLESCENTS AND ADULTS PROTOCOL 321 SPONSOR: AVENTIS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: 12 WEEK TREATMENT WITH 250 MCG ROFLUMILAST VS PLACEBO IN PATIENTS WITH ASTHMA PROTOCOL BY217/FK1 020 SPONSOR: ALTANA-BYK GULDEN PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, OPEN LABEL, LONG TERM 1 YEAR SAFETY STUDY OF CICLESONIDE 100 MCG DAILY, MDI ADMINISTERED ONCE DAILY FOR TREATMENT OF MILD TO MODERATE PERSISTENT ASTHMA IN ADOLSECENTS AND ADULTS PROTOCOL XRP1526B-326 SPONSOR: AVENTIS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLINE, PARALLEL GROUP COMPARISON OF THE SAFETY AND EFFICACY OF THREE ONCE DAILY DOSES OF BAY 19-8004 WITH PALCEBO AND MONTELUKAST 10 MG DAILY IN PATIENTS WITH SYMPTOMIATIC ASTHMA PROTOCOL BAY 19-8004 SPONSOR: BAYER PHARMACEUTICALS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, OPEN LABEL, RANDOMIZED, PARALLEL GROUP STUDY TO ASSESS THE LONG TERM SAFETY PERFORMANCE OF FEXOFENADINE COMPARED TO MONTELUKAST IN SUBJECTS WITH ASTHMA PROTOCOL M016344P/3003 SPONSOR: BAYER PHARMACEUTICALS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF FEXOFENADINE 120 MG BID IN SUBJECTS WITH MILD TO MODERATE PERSISTENT ASTHMA PROTOCOL M0164655P/3001 SPONSOR: AVENTIS PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: AN EFFICACY AND SAFETY STUDY OF LEVALBUTEROL, RACEMIC ALBUTEROL AND PLACEBO IN SUBJECTS TWELVE YEARS OF AGE AND OLDER WITH ASTHMA PROTOCOL 051-353 SPONSOR: SEPRACOR PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL STUDY COMPARING THE EFFICACY AND SAFETY OF FEXOFENADINE 120 MG BID, FEXAOFENADINE 240 MG QD, AND PLACEBO IN SUBJECTS WITH PERENNIAL ALLERGIC RHINITIS PROTOCOL M016455M/3002 SPONSOR: AVENTIS PRIMARY INVESTIGATOR: GARY A. COHE, MD TITLE: AN IN-USE STUDY OF THE DOSE INDICATOR FOR THE FLUNISOLIDE HFA INHALER SYSTEM REGULATORY PACKAGE PROTOCOL ANC-MD-21 SPONSOR: FOREST PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A PLACEBO CONTROLLED COMPARISON OF THE EFFICACY AND SAFETY OF THE CURRENT US VERSION OF PULMICORT (BUDESONIDE) TURBUHALER AND THE NEW VERSION OF PULMICORT TURBUHALER IN ASTHMATIC ADULTS AND ADOLESCENTS CURRENTLY TREATED WITH INHALED STEROIDS PROTOCOL SD-004-0620 SPONSOR: ASTRAZENECA PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A PLACEBO CONTROLLED COMPARISON OF THE EFFICACY AND SAFETY AND PHARMACOKINECTICS OF THE CURRENT US VERSION OF PULMICORT (BUDESNOIDE) TURBUHALER AND THE NEW VERSION OF PULMICORT TURBUHALER IN ASTHMATIC CHILDREN AND ADOLSECENTS PROTOCOL SD-004-0726 SPONSOR: ASTRAZENECA PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, BLINDED, MULTICENTER, PARALLEL STUDY COMPARING THE EFFICACY AND SAFETY OF PULMICORT RESUPLES (BEDESONIDE INHALATION SUSPENSION) AT 0.5 MG AD, 1.0 MG QD, 1.0 MG BID, 2.0 MG BID AND PULMICORT TURBUHALER (BUDESONIDE) AT 400 MCG BID IN ADOLSECENTS 12 YEARS OF AGE AND OLDER AND ADULTS WITH MODERATE TO SEVERE ASTHMA PROTOCOL SD-004-0764 SPONSOR: ASTRAZENECA PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, MULTICENTER, PLACEBO CONTROLLED PARALLEL GROUP S;TUDY OF FOUR MONTHS DURATION PER PATIENT TO EVALUATE THE SAFETY AND EFFICACY OF TREATMENT 24 MG BID AND 12 MG BID FORMOTEROL, DOUBLE BLIND AND 12 MG BID FORMOTEROL WITH ADDITIONAL ON DEMAND FORMOTEROL DOES, OPEN LABEL IN ADOLESCENT AND ADULT PATIENT WITH PERSISTENT STABLE ASTHMA PROTOCOL CFOR258D52307 SPONSOR: NOVARTIS PRIMARY INVESTOGATOR: GARY A. COHEN, MD TITLE: A 24 WEEK, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ROFLUMILAST (250 ,CG OR 500 MCG) DAILY IN PATIENTS WITH ASTHMA PROPTOCOL PDEAAS-1500-002 SPONSOR: PFIZER PHARMACIA PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF ORAL ALMOTRIPTAN 6.25 MG, 12.5 MG, AND 25 MG IN THE ACUTE TREATMENT OF MIGRAINE IN ADOLSECENTS PROTOCOL 638-CNS-0059-015 SPONSOR: PHARMACIA PRIMARY INVESTIGATOR: GARY A. COHEN, MD TITLE: A 52 WEEK RANDOMIZED, DOUBLE BLIND, SIMGLE DUMMY, PARALLEL GROUP, MULTICENTER PHASE III STUDY COMPARING THE LONG TERM SAFETY OF SYMBICORT PMDI 160/4.5 MG X 4 ACTUATION TWICE DAILY TO SYMBICORT PMDI 160/4.5 MG X 2 ACTUATIONS TWICE DAILY AND BUDESONIDE HFA PMDI 160 MG X 4 ACTUATIONS TWICE DAILY IN ADULT AND ADOLESCENT SUBJECTS WITH ASTHMA PROTOCOL SD-039-0728 SPONSOR: ASTRAZENECA PRINCIPLE INVESTIGATOR: GARY A. COHEN, MD TITLE: A RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED, PARALLEL GROUP, MULTICENTER, TWELVE WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF SYMBICORT PMDI 160/4.5 MCG (2 ACTUATIONS) ONCE DAILY (QD) COMPARED TO SYMBICORT PMDI 80/4.5 MCG (2 ACTUATIONS) QD, SYMBICORT PMDI 80/4.5 MCG (2 ACTUATIONS) BID AND TO BUDESONIDE PMDI 160 MCG (2 ACTUATIONS) QD IN ASTHMATIC SUBJECTS TWELVE YEARS OF AGE AND OLDER PROTOCOL D5896C00001 SPONSOR: ASTRAZENECA PRIMARY INVESTIGATOR: GARY A. COHEN, MD
|
||
|
Allergy & Asthma Prevention & Treatment Center
Tel: 858.458.0940
9833 Pacific Heights Boulevard
|